Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: PPARα ligand, AVE8134, and cyclooxygenase inhibitor therapy synergistically suppress lung cancer growth and metastasis

Fig. 3

AVE8134 inhibited endothelial proliferation, tube formation, and migration by activating PPARα. a and b Proliferation ability of human umbilical vein endothelial cells (HUVECs) treated with Wy, different doses of AVE, or the PPARα antagonist GW6471, as assessed by BRDU incorporation (n = 5–7). *P < 0.05 vs CON; #P < 0.05 vs AVE8134 (10 μM). c1 and c2 HUVECs were plated into Matrigel after the indicated treatment. Shown are the representative images of capillary-like structures (n = 6). *P < 0.05 vs CON; #P < 0.05 vs AVE8134 (10 μM). d1 and d2 Treated endothelial cells were plated into Boyden chambers and cell migration was assessed (n = 8). *P < 0.05 vs CON; #P < 0.05 vs AVE8134 (10 μM). e1-f2 Representative bands and the histogram of Cyp2c9/β-actin from HUVECs treated with Wy, different doses of AVE, or the PPARα antagonist GW6471 (n ≥ 3). *P < 0.05, vs control; #P < 0.05 vs AVE8134 (10 μM)

Back to article page